Amylin Pharmaceuticals Inc - Current report filing (8-K)
May 30 2008 - 4:11PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 30, 2008
AMYLIN PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or Other Jurisdiction of
Incorporation)
|
|
0-19700
(Commission File Number)
|
|
33-0266089
(I.R.S. Employer Identification No.)
|
9360 Towne Centre Drive
San Diego, California 92121
(Address of principal executive offices and zip code)
Registrants telephone number, including area
code:
(858)
552-2200
Check the appropriate box below if the Form 8K is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (
see
General
Instruction A.2. below):
¨
|
Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
|
|
|
¨
|
Soliciting material pursuant to Rule 14a12
under the Exchange Act (17 CFR 240.14a12)
|
|
|
¨
|
Precommencement communications pursuant to
Rule 14d2(b) under the Exchange Act (17 CFR 240.14d2(b))
|
|
|
¨
|
Precommencement
communications pursuant to Rule 13e4(c) under the Exchange Act (17
CRF 240.13e4(c))
|
Item
1.01. Entry into a Material Definitive
Agreement.
On May 30, 2008, the stockholders of Amylin Pharmaceuticals, Inc.
approved an amendment to Amylins 2001 Equity Incentive Plan to increase by 3,500,000
shares the aggregate number of shares of Amylins common stock authorized for
issuance under the plan. The amended and
restated plan is attached hereto as Exhibit 99.1 and is incorporated
herein by reference.
Item 9.01. Financial Statements
and Exhibits.
(d)
|
Exhibits.
|
|
|
|
|
|
Number
|
|
Description
|
|
|
|
|
|
99.1
|
|
Amylin
Pharmaceuticals, Inc. Amended and Restated 2001 Equity Incentive Plan.
|
2
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, as amended, the registrant
has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
AMYLIN
PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
Dated: May 30, 2008
|
By:
|
/s/ Lloyd A. Rowland
|
|
|
Lloyd A. Rowland
|
|
|
Vice
President, Governance and Compliance, and
Corporate Secretary
|
3
EXHIBIT
INDEX
Number
|
|
Description
|
|
|
|
99.1
|
|
Amylin
Pharmaceuticals, Inc. Amended and Restated 2001 Equity Incentive Plan.
|
4
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024